⌘K
Loading ticker…
As of 2026-08-25, First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) has a 3-month relative strength percentile of 99 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.7%, relative volume 0.69×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Not enough history to compute monthly seasonality for TRAX.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
TRAX is held by 25 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $2M notional. Top 3 carry $4M.
Held by 35 ETFs · $9M across latest filings · largest weight 0.53% (CANC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | new |
| VTWO | 0.01% | $1M | new |
| CANC | 0.53% | $932K | new |
| VHTVanguard Health Care ETF | 0.00% | $667K | new |
| VTWG | 0.02% | $270K | new |
| AVUSAvantis U.S. Equity ETF | 0.00% | $264K | new |
| OMFS | 0.09% | $242K | new |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $169K | new |
| ONEQ | 0.00% | $140K | new |
| GSSC | 0.01% | $124K | new |
Showing 10 of 25 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News